Kidney transplantation using complement inhibitor in a patient suffering from atypical hemolytic-uremic syndrome associated with factor H antibodies: successful prevention of recurrence of the underlying disease

Atypical hemolytic-uremic syndrome (aHUS) is an extremely rare complement-mediated disease that belongs to the group of thrombotic microangiopathies (TMA). It often reoccurs after kidney transplantation (KT). Previously, KT was considered contraindicated in both children and adults with aHUS due to high (up to 50% and above) incidence of early graft loss associated with post-transplant recurrent TMA. Introduction of specific complement inhibitor therapy into clinical practice has improved outcomes in patients with aHUS and has significantly reduced the risk of post-transplant recurrence of underlying disease. We describe the clinical observation of a 20-year-old female patient with aHUS associated with antibodies to factor H, a major regulator of complement activation. The patient underwent KT and eculizumab was used for prophylactic purposes. In the postoperative period, the patient developed ureteral necrosis that required reconstructive surgery, followed by graft pyelonephritis. Despite postoperative complications, which were highly likely to trigger uncontrolled complement activation, TMA recurrence was avoided due to early treatment of the complications and prophylactic use of complement inhibitor therapy.

atypical hemolytic-uremic syndrome, eculizumab, kidney transplantation, complement-activating conditions

1. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60. doi: 10.1186/1750-1172-6-60.

2. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015; 35 (5): 421–447. doi: 10.1016/j.nefro.2015.07.005.

3. Kozlovskaya NL, Prokopenko EI, Emirova KhM, Serikova SYu. Klinicheskije rekomendacii po diagnostike i lecheniju atipichnogo gemolitiko-uremicheskogo sindroma. Nefrologija i dializ. 2015; 17 (3): 242–264.

4. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010; 21: 2180–2187. doi: 10.1681/ASN.2010030315.

5. Reusz G. Atypical hemolytic uremic syndrome caused by primary complement defects. Orv Hetil. 2018; 159 (23): 929–936. doi: 10.1556/650.2018.31044.

6. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004; 43: 976–982. doi: 10.1053/j.ajkd.2004.02.010.

7. Davin JC, van de Kar N. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol. 2015; 6 (4): 171– 185. doi: 10.1177/2040620715577613.

8. Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K et al. Eculizumab in anti-factor H antibodies associated with atypical hemolytic uremic syndrome. Pediatrics. 2014; 133 (6): e1764–e1768. doi: 10.1542/peds.2013-1594.

9. Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int. 2017; 92 (5): 1261–1271. doi: 10.1016/j.kint.2017.04.028.

10. Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013; 27 (4): 117–125. doi: 10.1016/j.trre.2013.07.003.

11. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013; 13 (3): 663–675. doi: 10.1111/ajt.12077.

12. Jager NM, Poppelaars F, Daha MR, Seelen MA. Complement in renal transplantation: The road to translation. Mol Immunol. 2017; 89: 22–35. doi: 10.1016/j.molimm.2017.05.014.

13. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a «Kidney Disease: Improving Global Outcomes» (KDIGO) Controversies Conference. Kidney Int. 2017; 91 (3): 539–551. doi: 10.1016/j.kint.2016.10.005.

14. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A et al. HUS International: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016; 31 (1): 15–39. doi: 10.1007/s00467-015-3076-8.

15. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis. 2010; 55 (4): 708–711. doi: 10.1053/j.ajkd.2009.08.011.

16. Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014; 98 (11): 1205–1212. doi: 10.1097/ TP.0000000000000200.

17. Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017; 10 (3): 310–319. doi: 10.1093/ckj/sfw115.

18. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87 (5): 1061–1073. doi: 10.1038/ki.2014.423.

19. Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017; 30 (1): 127–134. doi: 10.1007/s40620-016-0288-3.

20. Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. with eculizumab: case report and review of the literature. Transpl Int. 2015; 28 (9): 1121–1125. doi: 10.1111/tri.12582.

21. Grenda R, Durlik M. Eculizumab in renal transplantation: a 2017 Update. Ann Transplant. 2017 12; 22: 550– 554. doi: 10.12659/AOT.905917.